What is the 13F Pro Quality Score for SCYX?

13F Pro ranks SCYNEXIS INC (SCYX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SCYX's current score at https://13fpro.ai/research/SCYX (free sign-up required for the full ranking).

Where does 13F Pro source SCYX data?

All SCYNEXIS INC fundamentals and ownership data come directly from SEC EDGAR. SCYNEXIS INC files with the SEC under CIK 1178253. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SCYX in?

SCYNEXIS INC (SCYX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SCYX research updated on 13F Pro?

SCYX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

SCYNEXIS INC(SCYX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1178253 SCYX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 45 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SCYX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for SCYNEXIS INC (SCYX), a Healthcare sector company. SCYX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 45 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), SCYNEXIS INC reports net income of $-21.3M, free cash flow of $-8.1M. Top institutional holders of SCYX by reported 13-F value include Squadron Capital Management, GREAT POINT PARTNERS, Avidity Partners Management, based on the most recent SEC filings. SCYX trades on the Nasdaq exchange and files with the SEC under CIK 1178253. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SCYX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SCYNEXIS INC directly from SEC EDGAR. SCYNEXIS INC's 13F Pro composite quality score has ranged between 9 and 75 since 2021, currently 8.9 — a declining long-term trajectory across 9 quarterly and live scoring snapshots.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-21.3M

Free Cash Flow

Q1 2026

$-8.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+304.7% YoY

$20.6MFY 2025

FY20 $0.00FY21 $13.2MFY22 $5.1MFY25 $20.6M

Net Income

+86.3% YoY

$-8.6MFY 2025

FY20 $-55.2MFY21 $-32.9MFY22 $-62.8MFY25 $-8.6M

Operating Income

+81.3% YoY

$-16.1MFY 2025

FY20 $-51.1MFY21 $-60.8MFY22 $-85.8MFY25 $-16.1M

EPS (Diluted)

+88.4% YoY

$-0.17FY 2025

FY20 —FY21 $-1.25FY22 $-1.47FY25 $-0.17

Total Assets

-32.8% YoY

$59.0MFY 2025

FY20 $102.5MFY21 $119.8MFY22 $87.8MFY25 $59.0M

Total Debt

—FY 2025

FY20 —FY21 $34.4MFY22 —FY25 —

Op. Cash Flow

+93.4% YoY

$-5.3MFY 2025

FY20 $-49.4MFY21 $-54.6MFY22 $-79.9MFY25 $-5.3M

Metric	FY 2025	FY 2022	FY 2021	FY 2020	FY 2019	FY 2017
Revenue	$20.6M +304.7%	$5.1M -61.3%	$13.2M	$0.00 -100.0%	$121.0K -52.9%	$257.0K
Net Income	$-8.6M +86.3%	$-62.8M -91.1%	$-32.9M +40.4%	$-55.2M -2.7%	$-53.7M -114.3%	$-25.1M
Operating Income	$-16.1M +81.3%	$-85.8M -41.0%	$-60.8M -18.9%	$-51.1M -4.6%	$-48.9M -85.9%	$-26.3M
EPS (Diluted)	$-0.17 +88.4%	$-1.47 -17.6%	$-1.25	—	—	—
Total Assets	$59.0M -32.8%	$87.8M -26.7%	$119.8M +16.9%	$102.5M +79.4%	$57.2M +24.7%	$45.9M
Total Debt	—	—	$34.4M	—	$0.00 -100.0%	$14.7M
Operating Cash Flow	$-5.3M +93.4%	$-79.9M -46.4%	$-54.6M -10.5%	$-49.4M -29.5%	$-38.1M -55.2%	$-24.6M

AI Insight: SCYX Financial Trends

Q4 2025 inflection reversed sharply in Q1 2026, with revenue collapsing to $0M and net loss widening to $21M despite prior quarter profitability.

• Q4 2025 showed dramatic turnaround: revenue jumped to $19M, net income swung to +$12M, operating income to +$11M, and operating cash flow to +$18M.

• Q1 2026 deterioration: revenue fell to $0M, net loss widened to $21M, operating income collapsed to $-17M, and equity fell to $41M from $49M.

• Equity erosion from $60M (Q2 2024) to $41M (Q1 2026) reflects cumulative operating losses and cash burn over nine quarters.

⚠ Q4 2025 revenue spike ($19M) and profitability may represent one-time event; Q1 2026 $0M revenue suggests no sustained commercial traction.

⚠ Equity capital declining sharply; at current burn rate, runway appears limited without external financing.

AI Insight: SCYX Ratio Trends

SCYNEXIS swung to profitability in Q4 2025 with 56% operating margin, but TTM remains deeply negative—suggesting a one-quarter turnaround rather than sustainable improvement.

• Operating margin jumped to 56.4% in Q4 2025 from negative throughout 2024–Q3 2025, with net margin at 65.7%.

• ROE and ROA both swung positive in Q4 2025 (99.3% and 83.1% respectively) after sustained losses in prior quarters.

• TTM remains severely negative: -120% operating margin, -120.5% net margin, -59.1% ROIC—indicating Q4 2025 profit offset by 3 quarters of losses.

⚠ Q4 2025 profitability spike appears isolated; no Q1 2026 data available to confirm sustainability or margin durability.

⚠ Three consecutive quarters of deteriorating ROIC (Q2–Q3 2025: -86.2% to -92.3%) preceded the Q4 reversal; source of turnaround unexplained.

Get alerted when SCYX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SCYNEXIS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SCYX

Squadron Capital Management LLC
$7.0M7,608,695 sh
GREAT POINT PARTNERS LLC
$6.9M7,554,347 sh
Avidity Partners Management LP
$1.9M2,081,660 sh
HEIGHTS CAPITAL MANAGEMENT, INC
$1.9M2,086,960 sh
KINGDON CAPITAL MANAGEMENT, L.L.C.
$1.8M1,982,491 sh
Empery Asset Management, LP
$1.7M1,847,826 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.4M1,564,398 sh
DAFNA Capital Management LLC
$996.6K1,086,956 sh
MILLENNIUM MANAGEMENT LLC
$570.5K622,161 sh
GEODE CAPITAL MANAGEMENT, LLC
$446.0K486,368 sh

Fund	Value	Shares
Squadron Capital Management LLC	$7.0M	7,608,695
GREAT POINT PARTNERS LLC	$6.9M	7,554,347
Avidity Partners Management LP	$1.9M	2,081,660
HEIGHTS CAPITAL MANAGEMENT, INC	$1.9M	2,086,960
KINGDON CAPITAL MANAGEMENT, L.L.C.	$1.8M	1,982,491
Empery Asset Management, LP	$1.7M	1,847,826
VANGUARD CAPITAL MANAGEMENT LLC	$1.4M	1,564,398
DAFNA Capital Management LLC	$996.6K	1,086,956
MILLENNIUM MANAGEMENT LLC	$570.5K	622,161
GEODE CAPITAL MANAGEMENT, LLC	$446.0K	486,368

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SCYX on your watchlist

Track score changes the day SCYNEXIS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SCYX a good stock to buy?

13F Pro's AI-powered analysis of SCYNEXIS INC (SCYX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SCYX are available on the SCYX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SCYX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SCYX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SCYNEXIS INC's investment landscape.